Fresenius Kabi
News
September 6, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend® (pegfilgrastim)
read moreAugust 18, 2022
Fresenius Kabi announces Acceptance of its Marketing Authorization Application by the European Medicines Agency for MSB11456, a Tocilizumab Biosimilar Candidate
read moreAugust 10, 2022
Fresenius Kabi establishes partnership with Bio-Manguinhos/Fiocruz and Bionovis to provide access to adalimumab biosimilar in Brazil
read moreAugust 2, 2022
Fresenius Kabi’s Biologics License Application for Biosimilar Candidate Tocilizumab Accepted for Review by the FDA
read moreAugust 1, 2022
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
read moreJuly 27, 2022
A biosimilar patient story: "I can live my life again and not feel fear"
read moreMay 23, 2022
EuroPN Study: New clinical data on medical nutrition therapy in critically ill patients
read moreApril 30, 2022
Fresenius Kabi SwissBioSim spreads smiles and happiness with a fundraising campaign
read moreApril 29, 2022
Fresenius Kabi Biosimilars team planted trees in Switzerland
read moreMarch 31, 2022
Next generation patient care: Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix
read more
- October 8 - 11, 2022
- |
- Austria, Vienna
UEG Week
United European Gastroenterology
- December 4 - 8, 2022
- |
- USA, Las Vegas
ASHP
Inspiring Change Across Pharmacy Practice
- December 6 - 10, 2022
- |
- USA, San Antonio
SABCS
San Antonio Breast Cancer Symposium
